Shares of cell therapy developer Fate Therapeutics shot up more than 8% Friday morning to $15.31 after the company announced that the FDA accepted its IND application for a cell therapy it’s developing called FT500 to treat advanced solid tumors.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,